Brinks attorney named Top Young Lawyer

Josh Ney, an associate attorney in the Ann Arbor office of Brinks Gilson & Lione, has been named a Top Young Lawyer by DBusiness magazine. It is the second year DBusiness has named six lawyers under the age of 40 as Top Young Lawyers. Ney and his fellow honorees appear in the July-August edition of DBusiness.

Ney joined Brinks in 2010 after serving as a summer associate in 2009. His practice focuses on patent litigation and patent prosecution in the pharmaceutical, biotechnology, chemical and medical device industries. Ney's litigation practice includes pharmaceutical patent litigation under the Hatch Waxman Act, as well as patent litigation related to chemical products and processes. In addition to his litigation docket, Ney prepares and prosecutes patent applications related to active pharmaceutical ingredients, pharmaceutical polymorphs, pharmaceutical formulations, synthetic processes, and methods of medical treatment. He has prosecuted patent applications leading to numerous U.S. and foreign patents. Ney is also involved with early stage product development processes, providing clearance analyses for clients' new products and IP due diligence to clients involved in mergers and acquisitions.

In addition to his case work, Ney has co-authored articles for Landslide Magazine (the American Bar Association intellectual property magazine) and IP Law360. The Landslide article was named one of the best ABA articles of 2011. In June 2014, Ney was selected by Managing Intellectual Property magazine as an IP Star.

Ney received a J.D. from the University of Michigan Law School, where he graduated cum laude, and a Ph.D. in chemistry from the University of Michigan. He earned his bachelor's degree in chemistry from Dartmouth, where he graduated magna cum laude. Ney received prestigious fellowships from Pfizer and from the American Chemical Society Division of Organic Chemistry while pursuing his Ph.D. He is a member of the American Chemical Society.

Published: Thu, Jul 10, 2014

Comments

  1. No comments
Sign in to post a comment »